Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix

Journal of Obstetrics and Gynaecology Research

Volumn 36, Issue 3, 2010, Pages 588-597

  Togami, Shinichi ^a   Nomoto, Mitsuharu ^b   Higashi, Michiyo ^b   Goto, Masamichi ^b   Yonezawa, Suguru ^b   Tsuji, Takahiro ^a   Batra, Surinder K ^c   Douchi, Tsutomu ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Disease free survival; Hazard ratio; MUC1 expression; MUC16 expression; Mucinous adenocarcinoma of the endocervical type; Overall survival

Indexed keywords

MUCIN; MUCIN 1; MUCIN 16; UNCLASSIFIED DRUG; CA 125 ANTIGEN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HAZARD RATIO; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OVARY METASTASIS; OVERALL SURVIVAL; PATHOLOGY; PROGNOSIS; RADICAL HYSTERECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE; UNIVARIATE ANALYSIS; UTERINE CERVIX CARCINOMA; COLLOID CARCINOMA; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; UTERINE CERVIX TUMOR; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN-1; PROGNOSIS; UTERINE CERVICAL NEOPLASMS;

EID: 77953343329     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01221.x     Document Type: Article

References (34)

1. Hollingsworth MA, Swanson BJ. Mucins in cancer: Protection and control of the cell surface. Nat Rev 2004 4 : 45 60.
2. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiolog Rev 2006 86 : 245 278.
3. Gipson IK, Blalock T, Tisdale A et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: In vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod 2008 78 : 134 142.
4. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 1994 25 : 364 372.
5. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997 47 : 813 830.
6. Utsunomiya T, Yonezawa S, Sakamoto H et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: Its relationship with the prognosis of the patients. Clin Cancer Res 1998 4 : 2605 2614.
7. Yonezawa S, Taira M, Osako M et al. MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas. Pathol Int 1998 48 : 319 322.
8. Higashi M, Yonezawa S, Ho JJ et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: Its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999 30 : 1347 1355.
9. Tamada S, Goto M, Nomoto M et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: Its relationship with tumor progression and prognosis. Pathol Int 2002 52 : 713 723.
10. Nakamura A, Horinouchi M, Goto M et al. New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: Its relationship with potential for malignancy. J Pathol 2002 197 : 201 210.
11. Matsukita S, Nomoto M, Kitajima S et al. Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Histopathology 2003 42 : 26 36.
12. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem 2001 276 : 27371 27375.
13. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 2001 22 : 348 366.
14. Vinh-Hung V, Bourgain C, Vlastos G et al. Prognostic value of histopathology and trends in cervical cancer: A SEER population study. BMC Cancer 2007 7 : 164.
15. Inoue T, Casanova HA, Morita K, Chihara T. The prognostic significance of the minimum thickness of uninvolved cervix in patients with cervical carcinoma stages IB, IIA, and IIB. Gynecol Oncol 1986 24 : 220 229.
16. Buckley CH, Beards CS, Fox H. Pathological prognostic indicators in cervical cancer with particular reference to patients under the age of 40 years. Br J Obstet Gynaecol 1988 95 : 47 56.
17. Ishikawa H, Nakanishi T, Inoue T, Kuzuya K. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 1999 73 : 42 46.
18. Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhorst TJ. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004 92 : 262 267.
19. Zhang WH, Wu LY, Bai P et al. [Prognostic factors of stage IB and IIA carcinoma of the cervix treated by surgery]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology] 2004 26 : 490 492.
20. Chargui R, Damak T, Khomsi F et al. Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol 2006 194 : 43 48.
21. Sevin BU, Nadji M, Lampe B et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995 76 : 1978 1986.
22. Lin HH, Cheng WF, Chan KW, Chang DY, Chen CK, Huang SC. Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Obstet Gynecol 1996 88 : 274 279.
23. Takeda N, Sakuragi N, Takeda M et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002 81 : 1144 1151.
24. Mitsuhashi A, Yamazawa K, Nagai Y, Tanaka N, Matsui H, Sekiya S. Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix. Ann Surg Oncol 2004 11 : 40 44.
25. Zhao S, Hayasaka T, Osakabe M et al. Mucin expression in nonneoplastic and neoplastic glandular epithelia of the uterine cervix. Int J Gynecol Pathol 2003 22 : 393 397.
26. Baker AC, Eltoum I, Curry RO et al. Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med 2006 130 : 1510 1515.
27. Feng H, Ghazizadeh M, Konishi H, Araki T. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002 32 : 525 529.
28. Morrison C, Merati K, Marsh WL, Jr. et al. The mucin expression profile of endometrial carcinoma and correlation with clinical-pathologic parameters. Appl Immunohistochem Mol Morphol 2007 15 : 426 431.
29. Ligtenberg MJ, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992 52 : 2318 2324.
30. Makiguchi Y, Hinoda Y, Imai K. Effect of MUC1 mucin, an anti-adhesion molecule, on tumor cell growth. Jpn J Cancer Res 1996 87 : 505 511.
31. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996 7 : 565 577.
32. Van De Wiel-Van Kemenade E, Ligtenberg MJ, De Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 1993 151 : 767 776.
33. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995 129 : 255 265.
34. Suwa T, Hinoda Y, Makiguchi Y et al. Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int J Cancer 1998 76 : 377 382.